|
Turkish Society of Cardiology
Young Cardiologists
President
Dr. Muzaffer Değertekin
Coordinator for the
Board of Directors
Dr. Ertuğrul Okuyan
Coordinator for the
Board of Directors
Dr. Can Yücel Karabay
Members
Dr. Adem Aktan
Dr. Gülşah Aktüre
Dr. Bayram Arslan
Dr. İnanç Artaç
Dr. Ahmet Oğuz Aslan
Dr. Görkem Ayhan
Dr. Ahmet Anıl Başkurt
Dr. Özkan Bekler
Dr. Oğuzhan Birdal
Dr. Yusuf Bozkurt Şahin
Dr. Serkan Bulgurluoğlu
Dr. Ümit Bulut
Dr. Veysi Can
Dr. Mustafa Candemir
Dr. Murat Çap
Dr. Göksel Çinier
Dr. Ali Çoner
Dr. Yusuf Demir
Dr. Ömer Furkan Demir
Dr. Murat Demirci
Dr. Ayşe İrem Demirtola Mammadli
Dr. Süleyman Çağan Efe
Dr. Mehmet Akif Erdöl
Dr. Kubilay Erselcan
Dr. Kerim Esenboğa
Dr. Duygu Genç
Dr. Kemal Göçer
Dr. Elif Güçlü
Dr. Arda Güler
Dr. Duygu İnan
Dr. Hasan Burak İşleyen
Dr. Muzaffer Kahyaoğlu
Dr. Sedat Kalkan
Dr. Yücel Kanal
Dr. Özkan Karaca
Dr. Ahmet Karaduman
Dr. Mustafa Karanfil
Dr. Ayhan Kol
Dr. Fatma Köksal
Dr. Mevlüt Serdar Kuyumcu
Dr. Yunus Emre Özbebek
Dr. Ahmet Özderya
Dr. Yasin Özen
Dr. Ayşenur Özkaya İbiş
Dr. Çağlar Özmen
Dr. Selvi Öztaş
Dr. Hasan Sarı
Dr. Serkan Sivri
Dr. Ali Uğur Soysal
Dr. Hüseyin Tezcan
Dr. Nazlı Turan
Dr. Berat Uğuz
Dr. Örsan Deniz Urgun
Dr. İdris Yakut
Dr. Mustafa Yenerçağ
Dr. Mehmet Fatih Yılmaz
Dr. Yakup Yiğit
Dr. Mehmet Murat Yiğitbaşı
Bulletin Editors
Dr. Muzaffer Değertekin
Dr. Bülent Mutlu
Dr. Süleyman Çağan Efe
Dr. Duygu İnan
Dr. Alper Karakuş
Dr. Sedat Kalkan
Dr. Göksel Çinier
Contributors
Dr. Selin Çakır
Dr. Ezgi Güzel
Dr. Numan Kılıç
Dr. Cansu Öztürk
Dr. Bilal Ülker
Dr. Gözde Yılmaz
|
| |
|
|
|
On-site Computed Tomography-derived Fractional Flow Reserve To Guide The Management Of Patients With Stable Coronary Artery Disease: The TARGET Randomized TrialTürk Kardiyoloji Derneği Genç Kardiyologlar Bülteni - On-site Computed Tomography-derived Fractional Flow Reserve To Guide The Management Of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial (Dr. Bilal Ülker)On-site Computed Tomography-derived Fractional Flow Reserve To Guide The Management Of Patients With Stable Coronary Artery Disease: The TARGET Randomized Trial
Dr. Bilal Ülker
Published in Congress: ACC2023
Objective:
Artificial intelligence-based computed tomography-derived fractional flow reserve (CT-FFR) plays an important role in the detection and management of coronary artery disease, but its efficacy is still questionable.
Methods: A total of 1,216 patients with stable coronary artery disease and 30%-90% lesions on CTA were randomized into CT-FFR and conventional treatment groups at 6 Chinese medical centers, and the primary endpoint was the proportion of patients undergoing invasive coronary angiography without obstructive coronary artery disease or with obstructive disease who did not require intervention within 90 days. Secondary endpoints included major adverse cardiovascular events (MACE), quality of life, angina symptoms and medical expenses at 1 year.
Results:
Baseline characteristics were similar in both groups, with 72.4% (881/1,216) having typical or atypical anginal symptoms. Invasive coronary angiography was performed in 421 (69.2%) of 608 patients in the CT-FFR group and 483 (79.4%) of 608 patients in the conventional treatment group. The proportion of patients who underwent invasive coronary angiography and did not have obstructive coronary artery disease or who had obstructive disease and did not undergo intervention was significantly reduced in the BT-FFR group (28.3% [119/421] vs. 46.2% [223/483] P<0.001). Overall, more patients in the BT-FFR group underwent revascularization (49.7% [302/608] vs. 42.8% [260/608], P=0.02), but there was no difference in MACE at 1 year (HR 0.88; 95%CI, 0.59 to 1.30). Quality of life and symptoms improved similarly in both groups during follow-up, with a trend towards lower costs in the CT-FFR group (difference, -¥4233; 95%CI, -¥8165 to ¥973, P=0.07).
Discussion:
AI-based CT-FFR reduced the proportion of patients with stable coronary artery disease without obstructive disease or undergoing invasive coronary angiography requiring intervention within 90 days, but increased revascularization overall without improving symptoms or quality of life or reducing major adverse cardiovascular events.
|
